Prevail Therapeutics (NASDAQ:PRVL) Rating Increased to Sell at BidaskClub

Prevail Therapeutics (NASDAQ:PRVL) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Tuesday, BidAskClub reports.

Other equities analysts also recently issued research reports about the company. Stifel Nicolaus began coverage on Prevail Therapeutics in a research report on Wednesday, July 15th. They issued a “buy” rating and a $23.00 target price on the stock. William Blair began coverage on Prevail Therapeutics in a research report on Monday. They issued an “outperform” rating and a $25.00 target price on the stock. ValuEngine raised Prevail Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, August 24th. Zacks Investment Research downgraded Prevail Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 14th. Finally, Wedbush upped their target price on Prevail Therapeutics from $19.00 to $22.00 and gave the company an “outperform” rating in a research report on Tuesday, May 26th. Two research analysts have rated the stock with a sell rating and nine have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $22.75.

NASDAQ:PRVL opened at $11.87 on Tuesday. The company has a quick ratio of 9.50, a current ratio of 9.50 and a debt-to-equity ratio of 0.07. The stock’s 50 day moving average price is $13.10 and its two-hundred day moving average price is $14.47. The firm has a market capitalization of $406.13 million, a price-to-earnings ratio of -5.01 and a beta of 1.19. Prevail Therapeutics has a 12-month low of $9.02 and a 12-month high of $19.96.

Prevail Therapeutics (NASDAQ:PRVL) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.07). Equities research analysts expect that Prevail Therapeutics will post -2.53 EPS for the current year.

A number of large investors have recently modified their holdings of PRVL. Avidity Partners Management LP acquired a new stake in Prevail Therapeutics during the second quarter worth approximately $15,329,000. BlackRock Inc. boosted its holdings in shares of Prevail Therapeutics by 59.3% in the 1st quarter. BlackRock Inc. now owns 1,133,979 shares of the company’s stock valued at $13,823,000 after purchasing an additional 422,205 shares in the last quarter. Federated Hermes Inc. acquired a new stake in shares of Prevail Therapeutics in the 2nd quarter valued at $2,645,000. Artal Group S.A. boosted its holdings in shares of Prevail Therapeutics by 85.0% in the 2nd quarter. Artal Group S.A. now owns 370,000 shares of the company’s stock valued at $5,513,000 after purchasing an additional 170,000 shares in the last quarter. Finally, QVT Financial LP acquired a new stake in shares of Prevail Therapeutics in the 1st quarter valued at $1,630,000. 82.59% of the stock is currently owned by institutional investors and hedge funds.

Prevail Therapeutics Company Profile

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

Featured Story: Marijuana Stocks Investing Considerations

Analyst Recommendations for Prevail Therapeutics (NASDAQ:PRVL)

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.